|
01 Jul 2021 |
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
|
|
01 Jul 2021 |
Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
|
|
01 Jul 2021 |
Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
|
29 Jun 2021 |
BRIM Biotechnology’s lead candidate BRM421 for Dry Eye Syndrome shows promising results in Phase II clinical trials
|
|
29 Jun 2021 |
Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
|
|
26 Jun 2021 |
Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis
|
|
25 Jun 2021 |
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
|
|
24 Jun 2021 |
Revolo Biotherapeutics Announces US FDA Approval of IND Application for Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis
|
|
24 Jun 2021 |
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
|
|
24 Jun 2021 |
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
|
|
24 Jun 2021 |
Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
|
|
17 Jun 2021 |
Novartis Receives FDA Breakthrough Therapy Designation for Investigational 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
|
16 Jun 2021 |
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
|
|
16 Jun 2021 |
Hugel America, Inc. Announces U.S. FDA Acceptance of Biologics License Application (BLA) for LetibotulinumtoxinA for Injection to Treat Glabellar (Frown) Lines
|
|
15 Jun 2021 |
Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China
|
|
13 Jun 2021 |
Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe
|
|
05 Jun 2021 |
Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
|
|
05 Jun 2021 |
Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)
|
|
04 Jun 2021 |
Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
|
|
04 Jun 2021 |
Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors
|
|
04 Jun 2021 |
U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)
|
|
03 Jun 2021 |
Lupin announces U.S. FDA acceptance for Pegfilgrastim Biosimilar application
|
|
29 May 2021 |
Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
|
|
27 May 2021 |
Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy
|
|
27 May 2021 |
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
|
